Respiratory Disease Flashcards
Asthma: Definiton
Chronic inflammatory condition associated with airway inflammation and hyper-responsiveness leading to reversible bronchial constriction.
> > childhood asthma, adult-onset asthma, exercise induced asthma, occupational asthma
Asthma: Epidemiology
8 million diagnosed with asthma in UK
5.4 million on asthma treatment
3 deaths per day due to asthma attacks
£1.1 billion on asthma each year
Asthma: Pathophysiology
> > exposure to irritants: cold air, exercise, smoke, pollution, allergen, medications
triggers type 1 hypersensitivity reaction mediated by IgE
T-helper 2 cells produce interleukins and cytokines
proliferation and recruitment of mast cells, eosinophils, goblet cells, neutrophils
these cells produce more inflammatory mediators»_space; MAST CELLS: leukotrines, histamine, prostaglandins
goblet cells cause mucus hypersecretion
> > airflow obstruction»_space; mucus, inflammation
broncho-hyperesponsiveness»_space; exaggerated broncho-constriction
inflammation
airway remodelling»_space; fibrotic and thickened smooth muscle
Asthma: Risk Factors
Genetic:
» gender
» atopy: eczema, hay-fever, allergic rhinitis
Environmental:
» exposure to allergens
» smoking
» exposure to animals
» socio-economic status
Other:
» stress
» medication
» diet and nutrition
» prenatal smoking
» recurrent respiratory infections
» occupation
Asthma: Symptoms
Wheeze
Chest tightness
Cough
Dysponea
Decreased exercise tolerance
All symptoms typically diurnal»_space; symptoms worse at night
Asthma: Signs
Between sthma exacerbations, clinical examination may be normal.
Tachypnoea
Use of accessory muscles
Polyphonic wheeze»_space; lots of different pitched noises
Hyperinflated chest
Hyper-resonant percussion note
Asthma: Diagnosis
History + examination + investigation
Asthma: Investigations
Spirometry-
» offered to all over 5 years
» blow into device as hard, fast, long as patient can
» FEV1/FEV ratio less than 70% = confirms airway obstruction
» then, do Bronchodilator Reversibility (BDR)»_space; give bronchodilator and do spirometry again
» if increase of over 12% in FEV1 and 200ml increase in FEV1 = positive result = diagnosable asthma
Fractional exhaled nitrix oxide testing (FeNO)-
» offered to all adults
» NO levels high in asthma patients due to eosinophilic inflammation
» a reading of over 40 part per billion (ppb) = positive
» if FeNO is positive = suggestive of asthma
Peak Expiratory Flow (PEF)-
» offered to all adults
» blow into device as hard and as fast as patient can
» peak flow diary 2x daily for 2-4 weeks
» over 20% variability between highest and lowest result = suggestive and diagnostic for asthma
Asthma: Extra Investigations
Respiratory exam: confirm symptoms and signs
CVS exam: rule out other causes of symptoms
ENT exam: polyps
X-ray
FBC: inflammatory cells
Sputum sample
Asthma: Investigations for Children
Children under 5 years-
» can’t perform objective testing
» use clinical judgement, signs and symptoms, and any positive results
Spirometery: 5-16yrs = FEV1 of 12% or more is positive
FeNO: 5-16yrs = result of 35ppb is positive
PEF: 20% variability is positive
Asthma: Management for Adults
For adults 17+
For young adults 5-16»_space; same but paediatric dose of ICS
GIVE SPACER FOR INHALERS
STEP 1: Prescribe an inhaled short-acting β2 agonist (SABA)as reliever therapy»_space; salbutamol, salamol, aeromir
STEP 2: Prescribe an inhaled corticosteroid (ICS) as preventer therapy»_space; clenil
STEP 3: Leukotriene receptor antagonists (LTRAs) orally as first-line add-on treatment to low dose ICS in adults»_space; montelukast
» recommended 4-8week trial period before LABA
STEP 4: Offer a long-acting beta-2 agonist (LABA) in combination with the ICS»_space; never LABA without ICS as risk of death
» no need to continue LTRA if not useful»_space; use clinical judgement
STEP 5: If still uncontrolled start MART treatment plan: fast onset LABA and ICS»_space; symbicort and fostair
» MART: maintenance and reliever therapy
STEP 6: MART plan: fast onset LABA with high dose ICS
Asthma: Stepping Up and Down
Asthma action plan»_space; (1) everyday asthma plan (2) when I feel worse (3) In an asthma attack
Review asthma plan yearly
Review patient after 6 months of changing treatment
If reliever inhaler needed more than 3 times per week»_space; poor management STEP UP NEEDED
USE ASTHMA CONTROL TEST
NICE guidline on complete control over asthma:
» no daytime symptoms due to asthma
» no limitations on daily activities due to asthma
» no night waking due to asthma
» no reliever needed
If complete control for minimum 3 months, consider STEP DOWN treatment
» aim for lowest step
» when reducing ICS, drop 25-50% every 3 months
Asthma: Management for Children
For children under 5 years
STEP 1: offer SABA for suspected asthma as reliever
STEP 2: consider 8-week trial for paediatric dose of ICS
STEP 3: after 8-weeks stop ICS treatment monitor
» if symptoms DON’T resolve, review diagnosis
» if symptoms DO resolve, but symptoms recur within 4 weeks of stopping, restart paediatric-dose ICS treatment for maintenance therapy
» if symptoms DO resolve, but symptoms recur after 4 weeks of stopping, repeat 4 week ICS trial period
STEP 4: addition of LTRA that are authorised for children
STEP 5: REFER
Acute Asthma: Definition
Acute severe asthma is an acute exacerbation of asthma that does not respond to standard treatments
Acute Asthma: Severity
Moderate-
» increasing symptoms
» PEFR > 50% of predicted or best
» no features of severe/life-threatening asthma
Severe-
» PEFR 33-50% of predicted or best
» heart rate > 110/min
» respiratory rate > 25/min
» unable to complete sentences in one breath.
» accessory muscle use
Life-threatening-
» PEFR < 33% of predicted or best
» Oxygen saturation < 92% or cyanosis
» normal PaCO2
» altered conciousness/confusion
» exhaustion
» poor respiratory effort
» hypotension
» silent chest
Acute Asthma: Risk Factors
Previous ITU admissions
Far along treatment steps
Acute Asthma: Investigations
PEFR: to help classify severity
Chest X-ray: exclude pneumothorax or consolidation
FBC : find cause
CRP: C-reactive protein is produced by the liver»_space; indicates inflammation in the body
ABG: check PaO2 and PaCO2
» if PaCO2 is normal = life threatening
» if PaCO2 is raised = near fatal
Acute Asthma: Management
IMMEDIATELY ADMIT
» oxygen, SABA, steroids
> > ABCDE assessment
oxygen to maintain saturations of 94-98%
SABA: 4 puffs initially, 2 puff every 2 minutes, upto 10 puffs OR nebulised SABA
steroids: oral prednisolone or IV hydrocortisone
> > nebulised ipratropium bromide»_space; SAMA
consider IV magnesium sulphate if patient not responding»_space; magnesium is CCB and causes bronchiodilation
ITU if no improvement
May require intubation and mechanical ventilation
Acute Asthma: Follow Up
Notify primary care within 24 hours
Follow up within 2 days of discharge
Check obs and peak flow
Address preventable contributors»_space; vaccines, smoking, mould
Ensure written plan
Set up regular therapy, as needed
Smoking Cessation
ENCOURAGE ALL PATIENTS TO STOP SMOKING
» stopping smoking can prevent 15 types of cancers
» smokers require higher doses of ICS for prevention
Pharmacological treatments-
» nicotine replacement therapies: nicotine patches, lozenge, chewing gum»_space; CANNOT CONTINUE SMOKING
» varenicline (champix): blocks nicotine receptors in brain, 12 week course, over 18 and not pregnant or breast feeding»_space; CAN CONTINUE SMOKING
» bupropion
Non-pharmacological treatments-
» vaping
» community support
» therapy and counselling
Acute Bronchitis: Definition
Inflammation of the bronchioles and mucus secretion
Acute Bronchitis: Pathophysiology
Commonly viral: influenza, rhinovirus, RSV
Sometimes bacterial
Acute Bronchitis: Risk Factors
Smoking
Damp or dusty environment
Acute Bronchitis: Symptoms
Healthy person with cough»_space; lasts 7-10 days but can persist upto 3 weeks
Pleuritic or retrosternal pain
Fever
Headache